This is a working overview of stability, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
== History == The name "riboflavin" comes from "ribose" (the sugar whose reduced form, ribitol, forms part of its structure) and "flavin", the ring-moiety that imparts the yellow color to the oxidized molecule (from Latin flavus, "yellow"). The reduced form, which occurs in metabolism along with the oxidized form, appears as orange-yellow needles or crystals. The earliest reported identification, predating any concept of vitamins as essential nutrients, was by Alexander Wynter Blyth. In 1879, Blyth isolated a water-soluble component of cows' milk whey, which he named "lactochrome", that fluoresced yellow-green when exposed to light. In the early 1900s, several research laboratories were investigating constituents of foods, essential to maintain growth in rats. These constituents were initially divided into fat-soluble "vitamine" A and water-soluble "vitamine" B. (The "e" was dropped in 1920.) Vitamin B was further thought to have two components, a heat-labile substance called B1 and a heat-stable substance called B2. Vitamin B2 was tentatively identified to be the factor necessary for preventing pellagra, but that was later confirmed to be due to niacin (vitamin B3) deficiency. The confusion was due to the fact that riboflavin (B2) deficiency causes stomatitis symptoms similar to those seen in pellagra, but without the widespread peripheral skin lesions. For this reason, early in the history of identifying riboflavin deficiency in humans the condition was sometimes called "pellagra sine pellagra" (pellagra without pellagra).
== Research == Neural drug delivery is the next step beyond the basic addition of growth factors to nerve guidance conduits. Drug delivery systems allow the rate of growth factor release to be regulated over time, which is critical for creating an environment more closely representative of in vivo development environments.
== RCM Beynon Prize == To mark the 80th birthday of John H. Beynon, the founding Editor of RCM, in 2004 an annual award was established in his honour by the publishers. The award is made on the recommendation of an ad hoc Sub-committee of the editorial board of RCM.
=== 1996–2004: Hiatus, side projects and death of Layne Staley === Although Alice in Chains never officially disbanded, Staley became a recluse, rarely leaving his Seattle condominium following the death of his ex-fiancée Demri Parrott on October 29, 1996. "Drugs worked for me for years," Staley told Rolling Stone in February 1996, "and now they're turning against me ... now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high. That's exactly what I didn't want to happen." Unable to continue with new Alice in Chains material, Cantrell released his first solo album, Boggy Depot, in 1998, also featuring Sean Kinney and Mike Inez. Cantrell and Kinney were also featured on Metallica's 1998 album Garage Inc., both were guest musicians in the track "Tuesday's Gone", a Lynyrd Skynyrd cover. In October 1998, Staley reunited with Alice in Chains to record two new songs, "Get Born Again" and "Died". Originally intended for Cantrell's second solo album, the songs were reworked by Alice in Chains and were released in the fall of 1999 on a box set, Music Bank. The set contains 48 songs, including rarities, demos, and previously released album tracks and singles. The band also released a 15-track compilation titled Nothing Safe: Best of the Box, serving as a sampler for Music Bank, as well as the band's first compilation album; a live album, simply titled Live, released on December 5, 2000; and a second compilation, titled Greatest Hits in 2001.
Sources: en.wikipedia.org
===== Lung ===== In 2019, a method for printing alveoli was developed in which 2D slices of photosensitive hydrogel are successively cured to form a 3D structure of the alveoli. This produces a soft material that is able to easily expand and contract, while also maintaining biocompatibility. The level of curing for the hydrogel is controlled using additive food coloring which absorbs light and increases the curing at that location. This allows the curing to be directed to better form 3D shapes. This method was able to form functional and vascularized alveoli. In 2021, this technique was improved by using an inkjet printing method, which increased the accuracy and precision of alveolar structure. With this ink-jet method, researchers were able to create functional portions of alveolar tissue with increased stability and surfactant secretion.
A wine fault or defect is an unpleasant characteristic of a wine often resulting from poor winemaking practices or storage conditions, and leading to wine spoilage. Many of the compounds that cause wine faults are already naturally present in wine but at insufficient concentrations to adversely affect it. However, when the concentration of these compounds greatly exceeds the sensory threshold, they replace or obscure the flavors and aromas that the wine should be expressing (or that the winemaker wants the wine to express). Ultimately the quality of the wine is reduced, making it less appealing and sometimes undrinkable. The yeast Brettanomyces produces an array of metabolites when growing in wine, some of which are volatile phenolic compounds. Brettanomyces converts p-coumaric acid to 4-vinylphenol via the enzyme cinnamate decarboxylase. 4-Vinylphenol is further reduced to 4-ethylphenol by the enzyme vinyl phenol reductase. 4-Ethylphenol causes a wine fault at a concentration of greater than 140 μg/L. Other compounds produced by Brettanomyces that cause wine faults include 4-ethylguaiacol and isovaleric acid. Coumaric acid is sometimes added to microbiological media, enabling the positive identification of Brettanomyces by smell. Geraniol is a by-product of the metabolism of sorbate. Fusel alcohols are a mixture of several alcohols (chiefly amyl alcohol) produced as a by-product of alcoholic fermentation.
=== Iron === Vegetarian diets typically contain amounts of iron similar to or higher than non-vegetarian diets, but the iron they provide is entirely non-heme, which is absorbed less efficiently than the heme iron found in meat, poultry, and seafood. For this reason, the Food and Nutrition Board of the National Academies sets the iron requirement for people following vegetarian diets at 1.8 times the Recommended Dietary Allowance for those who eat animal products. In estimating these values, mixed Western diets containing meat and ascorbic acid were judged to be about 15% bioavailable, while diets based mainly on cereals and vegetables were judged to be 10% bioavailable and very restricted vegetarian diets 5% bioavailable. Absorption of non-heme iron is strongly affected by other components of the same meal. Vitamin C and other organic acids increase absorption, so pairing iron-rich plant foods with citrus fruit, tomatoes, peppers, or broccoli improves uptake, while phytic acid in whole grains, legumes, nuts, and seeds, along with polyphenols in tea and coffee and high doses of calcium, inhibit it. Soaking, sprouting, and fermenting legumes and grains reduce their phytate content and improve iron availability. Plant foods that contribute meaningfully to iron intake include lentils, white beans, kidney beans, chickpeas, soybeans and tofu, spinach, cashews, pumpkin seeds, raisins, dark chocolate, and fortified breakfast cereals and breads, the last of which are among the largest sources of iron in fortified food supplies.
Sources: en.wikipedia.org
Abdominal obesity is typically associated with a statistically higher risk of heart disease, hypertension, insulin resistance, and type 2 diabetes (see below). With an increase in the waist to hip ratio and overall waist circumference the risk of death increases as well. Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance, type 2 diabetes, and an increased risk of developing cardiovascular disease. It is now generally believed that intra-abdominal fat is the depot that conveys the biggest health risk. Recent validation has concluded that total and regional body volume estimates correlate positively and significantly with biomarkers of cardiovascular risk and that BVI calculations correlate significantly with all biomarkers of cardiovascular risk. Abdominal obesity is linked with higher cardiovascular events among South Asian ethnic populations.
Todd appeared in more than 100 theatrical and television films and played opposite many major Hollywood stars. His film credits include: Platoon (1986), Night of the Living Dead (1990), Candyman (1992), The Crow (1994), The Rock (1996), Wishmaster (1997), the Final Destination series (2000–2025), Minotaur (2006), and Beg (2010). Todd was the voice of The Fallen in Transformers: Revenge of the Fallen (2009) and was also in the Rel Dowdell film Changing the Game. Todd was a special guest of the Weekend of Horror Creation Entertainment on May 23, 2010, and Screamfest LA. Todd portrayed Reverend Zombie in Hatchet II, which was released in a limited number of theatres on October 1, 2010. His signature baritone voice narrated several works, including the 2021 documentary Invisible Threads: From Wireless to War. Todd returned as William Bludworth, when he filmed Final Destination Bloodlines in 2024.
where P denotes the pressure of the system, V denotes the volume of the gas, k is a constant value representative of the temperature of the system and amount of gas. So long as temperature remains constant the same amount of energy given to the system persists throughout its operation and therefore, theoretically, the value of k will remain constant. However, due to the derivation of pressure as perpendicular applied force and the probabilistic likelihood of collisions with other particles through collision theory, the application of force to a surface may not be infinitely constant for such values of V, but will have a limit when differentiating such values over a given time. Forcing the volume V of the fixed quantity of gas to increase, keeping the gas at the initially measured temperature, the pressure P must decrease proportionally. Conversely, reducing the volume of the gas increases the pressure. Boyle's law is used to predict the result of introducing a change, in volume and pressure only, to the initial state of a fixed quantity of gas. The initial and final volumes and pressures of the fixed amount of gas, where the initial and final temperatures are the same (heating or cooling will be required to meet this condition), are related by the equation:
System description: System specifications are needed to procure an exact replacement after a disaster. Boot sector: The boot sector can sometimes be recreated more easily than saving it. It usually is not a normal file and the system will not boot without it. Partition layout: The layout of the original disk, as well as partition tables and filesystem settings, is needed to properly recreate the original system. File metadata: Each file's permissions, owner, group, ACLs, and any other metadata need to be backed up for a restore to properly recreate the original environment. System metadata: Different operating systems have different ways of storing configuration information. Microsoft Windows keeps a registry of system information that is more difficult to restore than a typical file.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.